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Abstract
Background: Cystic fibrosis (CF) is one of the most common fatal autosomal recessive disorders in the Caucasian population
caused by mutations of gene for the cystic fibrosis transmembrane conductance regulator (CFTR). New experimental
therapeutic strategies for CF propose a diet supplementation to affect the plasma membrane fluidity and to modulate
amplified inflammatory response. The objective of this study was to evaluate the efficacy of 5-methyltetrahydrofolate (5-
MTHF) and vitamin B12 supplementation for ameliorating cell plasma membrane features in pediatric patients with cystic
fibrosis.
Methodology and Principal Findings: A single arm trial was conducted from April 2004 to March 2006 in an Italian CF care
centre. 31 children with CF aged from 3 to 8 years old were enrolled. Exclusion criteria were diabetes, chronic infections of
the airways and regular antibiotics intake. Children with CF were supplemented for 24 weeks with 5-methyltetrahydrofolate
(5-MTHF, 7.5 mg /day) and vitamin B12 (0.5 mg/day). Red blood cells (RBCs) were used to investigate plasma membrane,
since RBCs share lipid, protein composition and organization with other cell types. We evaluated RBCs membrane lipid
composition, membrane protein oxidative damage, cation content, cation transport pathways, plasma and RBCs folate
levels and plasma homocysteine levels at baseline and after 24 weeks of 5-MTHF and vitamin B12 supplementation. In CF
children, 5-MTHF and vitamin B12 supplementation (i) increased plasma and RBC folate levels; (ii) decreased plasma
homocysteine levels; (iii) modified RBC membrane phospholipid fatty acid composition; (iv) increased RBC K
+ content; (v)
reduced RBC membrane oxidative damage and HSP70 membrane association.
Conclusion and Significance: 5-MTHF and vitamin B12 supplementation might ameliorate RBC membrane features of
children with CF.
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Introduction
Cystic fibrosis (CF) is one of the most common fatal autosomal
recessive disorders caused by mutations of gene for the cystic
fibrosis transmembrane conductance regulator (CFTR), which is a
member of the transporters acting as ATP-gated chloride channel
[1–6]. CF is a multiorgan disease mainly characterized by chronic
pulmonary infections and bronchiectasia, abnormal pancreatic
function, related to severe perturbation of its exocrine activities [1–
6]. In CF patients, the most common mutation in CFTR is the
deletion of a phenylalanine at position 508 (DeltaF508), which
favours abnormalities in CFTR folding with fast protein
degradation and loss of chloride conductance function [7–9].
In the last decade, the increased life expectancy of cystic fibrosis
(CF) patients has significantly modified their therapeutic end-
points [1–9]. In addition, studies on both CF animal models and
CF patients suggest that besides the CFTR gene mutation, other
defects such as altered activity of various membrane cation
transport systems [2,3], abnormal membrane phospholipid
composition, elevated turnover of essential fatty acids (EFAs)
[7,10–13] and oxidant-antioxidant imbalance, can contribute to
clinical manifestations of CF [14–17].
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supplementation to affect plasma membrane fluidity and to
modulate the cellular amplified inflammatory response in CF target
organs. In particular, previous works have suggested a link between
the CF clinical manifestations and the cell plasma membrane
fluidity as supported by the correction of some pathological
manifestations in supplemented CF mice [11,17–19]. Recently,
wehave reported acaseofachildwithCFwhohasbeenbeneficially
treated with 5-methyltetrahydrofolate (5-MTHF), the active form of
folic acid, since her birth. We observed amelioration of her clinical
state and significant changes in red cell membrane fatty acid
composition [20]. Based on these preliminary evidence, we
proposed that 5-MTHF improves the red cell membrane lipid
status through the increase in methionine production [21,22]. 5-
MTHF by its cofactor, vitamin B12, can deliver one-carbon unit to
the methionine cycle, which is essential for methylation reactions
and synthesis of DNA, RNA, proteins and phospholipids (PLs).
Through this pathway phosphatidylethanolamine (PE) receives
methyl groups from S-adenosyl-methionine (SAM) to form
phosphatidylcholine (PC). Methylated PE induces both the increase
in polyunsaturated fatty acid (PUFA) membrane concentration
[23,24] and the improvement of chloride channel activity as
supported by the in vitro evidence in mouse L-cells expressing the
deltaF508-CFTR mutated protein [24]. A defective methionine-
homocysteinemetabolismreducestheSAM-dependentmethylation
of PE, resulting in accumulation of PE and depletion of PC. An
abnormally increased plasma PE /PC ratio associated with lower
SAM and increased S-adenosylhomocysteine (SAH), has been
recently reported in children with CF compared to normal controls,
indicating a perturbation of the methylation pathway [25].
In normal adult patients, studies on 5-methyltetrahydrofolate (5-
MTHF), the active form of folic acid, have shown that 5-MTHF is
more effective than equimolar amount of folic acid in increasing
cell folate content [26–28] and that 5-MTHF at high dosages has a
safe profile [29]. In addition, 5-MTHF supplementation markedly
increases folate plasma levels and red cells folate content, which
can be used as a marker of long-term folate status, also being a
correlation with liver folate concentrations [30].
Red blood cells are an interesting and experimentally easy
accessible system to investigate plasma membrane, which shares
lipid, protein composition and organization with other cell types.
CFTRprotein[16,31–34]ispresentinhuman,mouseandrabbitred
cells; in CF patients is present as a mutated protein. Abnormalities in
red cell membrane essential fatty acid content and an increased
susceptibilitytooxidativedamagehavebeenrecentlydescribedinCF
patients,supportingtheuseofredcellsasacellmodelinCF[35–39].
Physiological studies on red cell membrane permeability in CF
patients are contradictory and not conclusive, most likely related to
the differences in the CF population studied [40–44].
The goal of our study was to evaluate in CF children the biological
efficacy of diet supplementation with the active form of folic acid (5-
MTHF) associated with vitamin B12 on red cell membrane features,
used as a paradigm for other cellular plasma membranes. In children
with CF we demonstrate that 5-MTHF and vitamin B12 supple-
mentation (i) increases plasma and red cell folate levels; (ii) decreases
plasmahomocysteinelevels;(iii)modifiesredcellmembranefattyacid
composition; (iv) increases red cell K
+ content; (v) reduces red cell
membrane oxidative damage; and HSP70 membrane association.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information ; see Checklist S1 and
Protocol S1.
Participants
We carried out a pre-protocol study in CF children and healthy
controls aged from 3 to 8 years old. We then conducted a single
arm trial from April 2004 to March 2006 in a population of CF
children referring to the CF Centre of Verona Hospital. Of 48
assessed CF children aged between 3 and 8 years old, thirty-one
patients were enrolled in the single-arm trial (Fig. 1). Exclusion
criteria were diabetes, chronic infections of the airways and
regular antibiotics intake. Genotype, clinical status and medica-
tions were recorded (Table 1). Patients were monthly checked.
Ethics
The study protocol was approved by the ethic committee of the
Verona Hospital and parents of children with CF provided written
informed consent before starting.
Interventions
CF children were supplemented for 24 weeks with 5-MTHF
and vitamin B12 respectively at the dosage of 7.5 mg/day and
0.5 mg/day Hospital. They were asked to maintain their usual
diet and the multivitamin supplementation (Protovit, Roche),
throughout the study. Supplements were taken every morning
before breakfast except on the blood sampling days when the
supplementation was taken after venipuncture.
We evaluated RBCs membrane lipid composition, membrane
protein oxidative damage, cation content, cation transport
pathways, plasma and RBCs folate levels and plasma homocys-
teine levels at baseline and after 24 weeks of 5-MTHF and vitamin
B12 supplementation.
Blood samples were collected into EDTA-coated tube and Na-
heparinized tube and immediately processed. Blood samples were
centrifuged and plasma was collected and stored at 280 C before
Figure 1. Consort style flowchart of participants through the
study.
doi:10.1371/journal.pone.0004782.g001
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choline washing solution (CWS) containing 172 mM choline
chloride, 1 mM MgCl2 and 10 mM Tris-MOPS (pH 7.4 at 4uC)
and used for evaluation of the following parameters: red cell cation
content, cation transport pathways and red cell membrane protein
profile.
Objectives
The objective of our study was to evaluate in CF children the
biological efficacy of diet supplementation with 5-MTHF and
vitamin B12 on red cell membrane features.
Determination of plasma and red cell folate content, of
plasma vitamin B12, plasma homocysteine and red cell
malondialdehyde levels
Both plasma and red cell folate and plasma vitamin B12 were
quantified using competitive immunoassay (Diagnostic Products
Corporation, USA). Plasma malondialdehyde and homocysteine
were determined using high-pressure liquid chromatography
(Chromsystems, Germany).
Plasma homocysteine concentrations (summation of homocys-
teine, homocystine and homocysteine-cysteine mixed disulphide,
free and protein bound), were determined by high performance
liquid chromatography (HPLC) according to a modification of the
method of Araki and Sako [45,46].
The plasma thiol compounds were reduced with tri-n-butylpho-
sphine and derivatized with a thiol specific fluorogenic reagent:
ammonium 7-fluoro-benzo-2-oxa-1,3-diazole-4-sulphonate. Sub-
sequently, derivatives were separated by reverse phase HPLC. The
fluorescence intensities were measured with excitation at 385 nm
and emission at 515 nm, using a Jasko FP-2020 plus fluorescence
spectrophotometer. Determination of intra- and inter-assay
precision was made by quantification of the homocysteine
concentration within a normal range plasma pool: the CV%
values were 2.5% and 3.5% respectively. The recovery tests were
.95%. The lowest validated detectable concentration of Hcy were
2 mmol/L.
Erythrocyte concentrations of MDA were determined by HPLC
according to a modification of the method of Agarwal and
Carbonneau [47,48]. 1 ml of samples were adjusted to pH 13,
using 50 ml of 10 mol/L NaOH and incubated in a 60uC water
bath for 30 min. The hydrolyzed samples were acidified to pH 1
with 500 ml of 586 g/L perchloric acid reagent. After centrifuging
at 10006g for 10 min, 0.3 ml of the supernate was added to 50 ml
of thiobarbituric acid reagent. The derivatives were separated by
reverse phase HPLC. The fluorescence intensities were measured
with excitation at 515 nm and emission at 553 nm, using a Jasko
Table 1. Clinical data of cystic fibrosis patients at baseline.
Patient Gender Age (yr) CFTR mutations BMI (kg/m2) FEV1 (%) Pancreatic sufficiency M.o. in sputum Antibiotic treatment
1 M 8 DF508/DF508 17,29 81 no no no
2 F 7 DF508/DF508 21,7 101 no P. aeruginosa C azithromycin p.o.
tobramycin neb.
3 F 6 DI507/711+5G A 22,5 91 no no no
4 F 5 DF508/not identified 15,2 NA no no no
5 M 8 DF508/DF508 15,4 92 no no no
6 M 7 N1303K/2789+5G A 19,2 73 no no no
7 F 7 DF508/621+1G T 15,1 82 no S. aureus no
8 F 8 DF508/1717-1G T 18,3 91 no S. aureus no
9 F 8 DF508/not identified 21,2 95 yes no no
10 F 7 DF508/2789+5G A 14,4 93 no no no
11 M 8 DF508/2789+5G A 15,9 106 yes no no
12 F 7 R1162X/R1162X 17,15 78 no S. aureus no
13 M 8 DF508/not identified 15,2 63 no no no
14 M 6 DF508/DF508 17,1 115 no P. aeruginosa I ciprofloxacin p.o.
tobramycin neb.
15 F 8 DF508/R1162X 14 49 no P. aeruginosa C azithromycin p.o.
tobramycin neb.
16 M 5 G542/1717-1G A 16,5 NA no no No
17 F 5 DF508/not identified 13,3 NA no P. aeruginosa I ciprofloxacin p.o.
tobramycin neb.
18 M 4 DF508/G542X 15,7 NA no no no
19 F 7 DI507/R1162X 16,5 94 no no no
20 F 4 DF508/Q552X 13,5 NA no no no
21 M 8 DF508/R1162X 13,8 78 no no no
22 F 6 2183AA G/N1303K 16,8 102 no no no
P.: Pseudomonas; S.: Staphylococcus; H.: Haemophilus; C: chronic colonization; I: intermittent colonization; NA: not applicable; p.o.: per os; neb.: nebulized.
doi:10.1371/journal.pone.0004782.t001
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between 87 and 100%.
Measurement of red cell membrane fatty acid
composition
Individual phospholipids were separated by thin layer chroma-
tography (TLC) in one dimension on 20 cm620 cm silica plates
(art. 5715, Merck, Darmstadt, Germany) which were previously
washed with methanol in order to remove impurities and dried.
TLC developing chamber was lined with chromatography paper
on all sides. Solvents for TLC were mixed by vigorous shaking,
added to the tank and allowed to equilibrate for 2 hours before the
run. The samples were applied 2 cm from the bottom of the plate,
as narrow bands (10 mm) with continuous application of
lukewarm air. The plates were run in chloroform:methanol:acetic
acid:water (25:15:3:1,5 v/v/v/v). The run was stopped when the
solvent front reached the top and the plate was fully dried with a
hair dryer (cold air). After exposure of the TLC plate to iodine
vapour, each phospholipid class was scraped off and extracted with
2 ml of methanol:benzene (1.5:0.5 v/v) mixture. A one-step
transesterification reaction was performed according to Lepage
[49], in order to generate fatty acids methylesters. As previously
described [50], a gas chromatographic (5890 gas chromatograph,
Hewlett Packard, Palo Alto, CA, USA) method was used to
separate and estimate fatty acids. Analysis was performed in
duplicate on each sample, peak identification was done with
commercially available reference fatty acids (Sigma) and heptade-
canoic acid (C17:0) was used as internal standard. Fatty acid
results are expressed as g/100 g total fatty acids. We used
unsaturation index (UI), as parameter to evaluate membrane
fluidity [51]. UI was calculated by the sum of (number of double
bonds in each fatty acids x % each fatty acid).
Measurements of red cell cation content and Na/K pump,
Na/K/2Cl cotransport and Na/H exchange activities in red
cells
Erythrocyte Na
+ and K
+ content were determined by atomic
absorption spectrometry (ANALYST 2000, Perkin-Elmer) using
standards in double-distilled water [52–54]. Cation transport
activities were estimated according to previously published
methods [52–54].Briefly, the maximal rates of Na/K pump and
Na/K/Cl cotransport (cot) actitvities were measured in
50 mmol L
21 of cells containing equal amounts of Na
+ and K
+.
With this procedure the internal sites for both transport systems
were saturated. The nystatin loading solution contained
70 mmol L
21NaCl, 70 mmol L
21 KCl and 55 mmol L
21 su-
crose. The Na/K pump was estimated as ouabain sensitive
fraction of Na efflux into a medium containing 130 mmol L
21
choline chloride and 10 mmol L
21 KCL. The ouabain concen-
tration was 0.1 mmol L
21, Na/K/Cl/ COT estimated as
bumetamide sensitive fraction of Na efflux into a medium
containing 140 mmol L
21 choline chloride and 0.1 mmol L
21
oubain. The bumetamide concentration was 0.01 mmol L
21. All
media contained 1 mmol L
21 MgCl2, 10 mmol L
21 glucose, and
10 mmol L
21 Tris-MOPS pH 7.4. The Na/H exchange rate was
evaluated as the amiloride-sensitive Na
+ efflux stimulated by
hypertonic shrinkage from cells containing equal amounts of Na
+
and K
+. The media contained 140 mmol L
21 choline Cl and the
osmolarity was increased with sucrose. The 5-N,N-hexamethyle-
neamiloride 10 mmol L
21 final concentration was used as a
specific inhibitor of the system.
Red cell membrane ghost preparation
Red cell ghosts were obtained as previously described [55].
Briefly, red cells were washed 4 times with choline washing
solution (in mM CWS: 155 choline chloride, 1 MgCl2, 10 Tris-
Mops pH 7.4 at 4uC, 295–300 mOsm). Red cell ghosts were
obtained lysing 1 volume of packed red cells in 10 volumes of ice
cold Phosphate Lysis Buffer (in mM PLB: 5 Na2HPO4 pH 8.0, in
presence of protease inhibitor cocktail tablet, 3 benzamidine, 1
Na3VO4). Samples were incubated for 10 min in ice and
centrifuged for 10 min at 12,000 g, 4uC. Ghosts were then
washed four times (centrifuging at 12,000 g, 4uC) with PLB until
they appeared almost white and used for either fluorescein-5-
maleimide analysis or electrophoresis analysis.
Red cell membrane protein oxidative damage was evaluated
using fluorescein-5-maleimide, which labels the proteins with
active thiol-groups [55]. Red cell ghost were diluted with buffer
(PBS) to final volume of 1 ml at 4uC. Fluorescein-5-maleimide was
solubilized in PBS (0.25 mg/ml). Red cell ghost were then
incubated with fluorescein-5-maleimide for 1 hour at room
temperature under dark. Red cell ghost were washed 5 times
with PBS, then were mixed with sample buffer and separated by
mono- dimensional electrophoresis (GE Healthcare). Fluorescence
Table 2. Data of healthy subjects and cystic fibrosis (CF) patients.
Controls CF patients p-value
Age (years) 5.962.1 6.761.4
Sex (M/F) 5/5 9/13
MTHFR 677 C.T polymorphism NA w/w 42 %
NA w/m 35 %
NA m/m 23 %
Plasma folate (ng/ml) 5.88 (4.07–6.74) 6.62 (4.99–8.16) 0.174
RBCs folate (ng/ml) 49.4 (27.03–82.8) 451.5 (339.0–708.0) 0.004
Plasma vitamin B12 (pg/ml) 896 (660–1055) 1157 (871–1448) 0.159
Plasma homocysteine (mmol/l) 6.90 (6.70–7.90) 7.50 (6.85–8.50) 0.424
RBCs MDA (mmol/g Hb) 12.65 (11.45–13.85) 13.70 (11.90–16.30) 0.232
RBCs: red blood cells; N: rare mutation; NA: not applicable; MTHFR: methylenetetrahydrofolate reductase; w/w: wild; w/m: heterozygote; m/m: mutant; MDA:
malondialdehyde. Data are summarized as mean6sd for age, frequency for sex and genotype, medians and interquantile ranges for folate, vitamin B12, homocysteine
and MDA.
doi:10.1371/journal.pone.0004782.t002
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photographed and analyzed. The bands showing different
fluorescence were excised in the corresponding Colloidal Coo-
massie stained gels and used for protein identification by MALDI-
TOF [56,57].
MALDI-TOF MS analysis and database search
The bands from 1D gels differently expressed in Colloidal
Coomassie stained gels were excised, destained (in DS: 50%
Acetonitrile, 5 mM NH4HCO3), dehydrated in 100% acetonitrile
and digested overnight at 37uC with a trypsin solution (0.01 mg/
ml trypsin, 5 mM NH4CO3). Mass spectra analysis was performed
using a Tof-spec SE (Micromass, Manchester, UK) or MALDI-
Micro MX mass spectrometer with PSD technology (Micromass,
Manchester, UK). Peptide spectra were obtained in positive ion
mode over the m/z range of 800–4000 Da range or 1000–
3000 Da in reflectron mode. Peptide solution was prepared mixing
equal volumes of matrix (matrix: a-cyano-4-hydroxy-cynnamic
acid 8 mg in 40% acetonitrile, 60% of 0.1% trifluoracetic acid).
100–120 laser shots were summed for each MS spectrum.
Database searching was performed using the measured peptide
masses against the Swiss-Prot database (taxa human) using the
MASCOT search engine (Matrix Science Ltd, London, UK) Only
protein identifications with significant Mascot score (p,0.05) were
Figure 2. The intracellular folate metabolism. (A) Human cells receive exogenous 5-methyltetrahydrofolate (5-MTHF) from the bloodstream
and produce endogenous 5-MTHF through the irreversible methylenetetrahydrofolate reductase (MTHFR) reaction that catalyzes the reduction of
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. 5-MTHF serves as methyl donor in the remethylation of homocysteine to methionine,
which in turn is converted to S-adenosylmethionine (SAM). The transmethylation reaction, which requires vitamin B12 and the methionine synthase
enzyme, converted 5-MTHF in tetrahydrofolate (THF). As 5-MTHF is a poor substrate for folylpolyglutamate synthetase, this enzyme adds glutamyl
residues to non-methylated folates, guaranteeing the intracellular folate retention. (B) A reduced activity of the methionine synthase activity or a
deficit of vitamin B12 causes a reduction of the intracellular folates. In fact, 5-MTHF leaks out of cells because cells cannot accumulate it, being
monoglutamised and therefore shorter than other intracellular folates. Conversely, (C) a reduced activity of the methylenetetrahydrofolate reductase
(MTHFR) causes the non-methylated folate accumulation, because these folates are polyglutamised by folylpolyglutamate synthase. (D) Immunoblot
analysis of methythertrahydrofolate reductase (MTHFR) protein expression in red cells from healthy controls and in CF patients. One representative
gel of other 20 with similar results. Graph reporting the immuno-blot analysis for the quantification of MTHFR expression as detected by
densitometry in normal controls (black bar) and in CF patients (gray bar); data are presented as percentage of baseline values (n=20).
doi:10.1371/journal.pone.0004782.g002
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missed cleavage were allowed for each matching peptide. Searches
were not constrained by pI or molecular weight [56,57].
Immunoblot analysis for methylterahydrofolate
reductase (MTHFR) and heat Shock Protein-70 (HSP70) in
red cells
Red cell membrane ghost were solubilized and separated by
mono-dimensional electrophoresis, transferred to membrane and
probed with specific antibodies: anti-Methylenetetrahydrofolate
reductase (MTHFR, clone N-20) antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); anti- heat shock protein 70
(HSP70, clone K-20) antibody was from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA).
Statistical methods
Wilcoxon rank-sum test was used to compare differences
between healthy children and CF children at baseline in plasma
and red cell folates, plasma vitamin B12, plasma homocysteine,
red blood cell MDA, membrane ion pathways, red cell cation
content and fatty acid percentages bound either to phosphatidyl-
ethanolamine (PE) or to phosphatidylcholine (PC).
Wilcoxon signed-rank test was used to compare differences
between CF children at baseline and after 5-MTHF and vitamin
B12 supplementation in fatty acid percentages bound either to PE
or to PC.
Results
Pre-protocol study: cystic fibrosis patients show increased
red cell folate content and abnormal red cell features
In the pre-protocol study, we evaluated the baseline character-
istics of 10 healthy controls and 22 children with CF who
participated at the trial and (Table 2). In CF patients, plasma
folate levels were similar to healthy children while red cell folate
content was significantly higher. Plasma vitamin B12 concentra-
tion was increased in children with CF compared to healthy
subjects, most likely related to the presence of this vitamin in low
quantity in multivitamin tablets assumed by CF children before
the study. Plasma homocysteine levels were similar in CF patients
and healthy children, while previous studies reported an increase
in plasma homocysteine levels in CF subjects. This discrepancy
might be related to diet differences between populations.
The increase in red cell folate content was unexpected,
suggesting that folates may accumulate as non-active form in red
cells of CF patients. Previous reports in other cell types indicate
that intracellular folates can be present as active form, or 5-
methyltetrahydrofolate (5-MTHF), and non-active forms as
polyglutamated folates [58–60]. While non-methylated folates
cannot cross the plasma membrane and might function as cellular
reservoir, 5-MTHF can easily cross the cell membrane. The
intracellular production of 5-MTHF is dependent on methylene-
trahydrofolate reductase (MTHFR) activity (Fig. 2A) [58]. Thus,
we hypothesized that in CF patients the intracellular non-
methylated folates are accumulated, while the 5-MTHF is not
produced, most likely due to alterations of MTHFR activity
(Fig. 2C), as also supported by the normality of vitamin B12 cell
content, whose deficiency can contribute to folate trapping in cells
(Fig. 2B) [59,60]. In order to validate this hypothesis, we evaluated
the incidence of C677T methylenetrahydrofolate reductase
(MTHFR) polymorphisms in the studied CF patients and no
differences were observed compared CF to historical controls of
local population (Table 2) [61]. We then evaluated the protein
expression of MTHFR in red cells from normal and CF children.
As shown in Fig. 2D, MTHFR protein expression was similar in
normal and CF red cells, suggesting that the alteration of 5-
MTHFR function might be most likely responsible for the
increased red cell folate content in CF patients.
Abnormalities of MTHFR function, determining reduced
biological availability of 5-MTHF, might promote alteration of
membrane lipid status and abnormal oxidative scavenging [21–
23]. In fact, 5-MTHF increases the methionine production, which
promotes the phosphatidylethanolamine (PE) methylation with
increased binding of polyunsaturated fatty acids (PUFAs) [23].
Thus, we evaluated membrane phospholipid fatty acid composi-
tion of red cells and monocytes from CF patients. As shown in
Table 3, polyunsaturated fatty acids (PUFAs) were lower in red cell
phospholipids of CF subjects than in healthy controls, confirming
a previous report [25] and suggesting a possible perturbation in
fatty acid metabolism [24,25]. Similar data were also observed in
CF monocytes (data not shown). The unsaturation index (UI), that
is the sum of all double bonds in fatty acid chains, was slightly
reduced in both red cells and monocytes from CF patients
compared to healthy children (CF RBCs UI: 144.9610.1 vs
normal RBCs: 145.8162.31; CF- monocyte UI: 133.5613.07 vs
normal 134.464.21), but it did not reach significance.
Previous reports have suggested that 5-MTHF exerts antioxi-
dant properties as scavenger of peroxynitrite [62]. Thus, the
following parameters of oxidative damage we evaluated: red cell
levels of malondialdehyde (MDA) as lipid peroxidation end
product [63] and the membrane protein binding of fluorescein-
5-maleimide, which labels proteins at level of active thiol-groups,
as marker of membrane protein oxidative damage [55]. Red cell
MDA content was slightly but not significantly higher in CF
patients compared to normal subjects (Table 2). As shown in
Fig. 3A, we observed reduced fluorescence intensity of red cell
membrane proteins in CF patients compared to healthy subjects,
suggesting increased membrane protein oxidative damage in red
cells from CF patients.
Table 3. Comparison of red cell phospholipid fatty acid
composition in healthy subjects and patients with cystic
fibrosis (CF).
Phospholipid
fatty acids Controls CF patients p-value
PE SFA 61,1 (60,6–61,8) 67,8 (52,2–69,0) 0,317
MUFA 18,6 (18,2–19,8) 27,2 (26,0–33,5) 0,019
PUFA 19,6 (18,2–20,7) 5,1 (3,4–9,9) 0,002
UFA 38,9 (38,2–39,4) 33,2 (31,0–47,8) 0,317
W3 1,1 (1,1–1,4) 0,5 (0,4–0,6) 0,019
W6 18,2 (17,1–19,3) 4,6 (3,1–8,4) 0,002
PC SFA 60,7 (58,1–60,8) 74,3 (67,5–78,1) 0,002
MUFA 24,1 (23,8–24,5) 18,4 (16,6–24,3) 0,125
PUFA 16,2 (15,3–19,5) 7,6 (4,0–8,3) 0,002
UFA 39,3 (39,2–41,9) 25,7 (21,9–32,5) 0,002
W3 ,0,01 (,0,01–
,0,01)
0,4 (0,3–0,5) 0,002
W6 16,2 (15,3–19,5) 7,3 (3,5–8,1) 0,002
PE: phosphatidylethanolamine; PC: phosphatidylcholine; SFA: saturated fatty
acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids;
UFA: unsaturated fatty acids; W3: n-3 fatty acids; W6: n-6 fatty acids. Data are
summarized as medians and interquantile ranges.
doi:10.1371/journal.pone.0004782.t003
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cation content and the activity of membrane cation transport
pathways, we evaluated the red cell Na
+ and K
+ content and the
activities of the main cation transport pathways in CF children and
in normal controls. In CF patients, Na
+ and K
+ content was
significantly lower than in normal controls (Fig 3B), while no
significant differences were observed in the activity of main
membrane cation transport systems (Fig. 3C). Interestingly, the
activity of the Na/K pump was slightly but not significantly
decreased in CF patients compared to healthy children (Fig. 3C).
Baseline data suggest reduced membrane fluidity and increased
pro-oxidant environment in CF red cells, affecting both lipid
composition and protein components of red cell membrane. Thus,
we investigated whether dietary supplementation with 5-MTHF, the
active form of folic acid, and vitamin B12, might by-pass the hypo-
thesized functional block of MTHFR and ameliorate red cell features.
Figure 3. Membrane proteins, ion content and cation transport pathways of red blood cells from healthy controls and CF patients.
(A) Red cell membrane proteins were separated by mono-dimensional electrophoresis and labelled with fluorescein-5-maleimide, which labels the
proteins with active thiol-groups. Fluorescence was detected by placing the gel on a UV light source, photographed and analyzed. One
representative gel of other 10 with similar results. (B) Red cell Na
+ and K
+ content in healthy controls and CF patients at baseline and after 5-MTHF
and vitamin B12 supplementation for 24 weeks. Data are reported as medians (range for controls: RBCs Na
+ 28.4–74.3 mmol/Kg Hb, RBCs K
+ 320–
512 mmol/Kg Hb n=10; CF at baseline: RBCs Na
+ 19.2–41.6 mmol/Kg Hb, RBCs K
+ 199.7–335 mmol/Kg Hb n=20; CF supplemented with 5-MTHF and
vitamin B12: RBCs Na
+ 15.6–61 mmol/Kg Hb, RBCs K
+ 236–447 mmol/Kg Hb, n=11); * P,0.05 compared to control red cells; u P,0.05 compared to
untreated CF patient red cells. (C) Cation transport pathways of red cells from controls (n=10) and CF patients at baseline (n=11) and after
supplementation (n=11). Data are expressed as medians (range for controls: Na-K pump 4.1–6.2 mmol610
13 cells6hour, Na-K-2Cl cotransport 0.98–
1.90 mmol610
13 cells6hour, Na-H exchange 0.68–1.2 mmol610
13 cells6hour; CF baseline: Na-K pump 3.28–11 mmol610
13 cells6hour, Na-K-2Cl
cotrasnport 0.15–1.70 mmol610
13 cells6hour, Na-H exchange 0.21–1.20; CF supplemented: Na-K pump 3.70–10.0 mmol610
13 cells6hour; Na-K-2Cl
cotrasnport 0.49–4.70 mmol610
13 cells6hour; Na-H exchange 1.0–5.0 mmol610
13 cells6hour); * P,0.05 compared to control red cells; u P,0.05
compared to untreated CF patient red cells.
doi:10.1371/journal.pone.0004782.g003
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PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4782Figure 4. Effects of 5MTHF and vitamin B12 supplementation on levels of plasma and red cell folate, of plasma vitamin B12 and
homocysteine in CF patients. (A) Plasma folate levels were 6.62 ng/mL (range: 4.99–8.16 ng/mL) at baseline and 52.85 ng/mL (range: 47.95–
60.51 ng/mL) after supplementation; (B) red cell folate levels were 451.50 ng/mL (range: 339.00–708.00 ng/mL) at baseline and 4800.27 ng/mL
(range: 3624–6249 ng/mL) after supplementation; (C) plasma vitamin B12 levels were 1157 pg/mL (range: 871–1448 pg/mL) at baseline and
2697.09 pg/mL (range: 2463–2963 pg/mL), after supplementation; (D) plasma homocysteine levels were 7.50 mM/L (range: 6.85–8.50 mM/L) at
baseline and 5.30 mM/L (range: 4.42–6.21 mM/L) after supplementation.
doi:10.1371/journal.pone.0004782.g004
Table 4. Effects of 5-methyltetrahydrofolate and vitamin b12 supplementation on red cell phospholipid fatty acid composition of
patients with cystic fibrosis (CF).
Phospholipid fatty acids CF baseline CF after supplementation p-value
PE SFA 67,8 (52,2–69,0) 66,6 (52,0–67,0) 0,138
MUFA 27,2 (26,0–33,5) 27,7 (27,0–33,0) 0,952
PUFA 5,1 (3,4–9,9) 5,8 (5,2–12,4) 0,038
UFA 33,2 (31,0–47,8) 33,4 (33,0–48,0) 0,26
W3 0,5 (0,4–0,6) 0,6 (0,4–0,7) 0,514
W6 4,6 (3,1–8,4) 5,1 (4,8–10,9) 0,028
PC SFA 74,3 (67,5–78,1) 76,7 (68,9–78,5) 0,161
MUFA 18,4 (16,6–24,3) 18,1 (15,5–23,4) 0,161
PUFA 7,6 (4,0–8,3) 7,3 (3,8–8,2) 0,123
UFA 25,7 (21,9–32,5) 23,3 (21,5–31,1) 0,161
W3 0,4 (0,3–0,5) 0,3 (0,3–0,4) 0,182
W6 7,3 (3,5–8,1) 7,1 (3,4–7,9) 0,161
PE: phosphatidylethanolamine; PC: phosphatidylcholine; SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids; UFA:
unsaturated fatty acids; W3: n-3 fatty acids; W6: n-6 fatty acids. Data are summarized as medians and interquantile ranger.
doi:10.1371/journal.pone.0004782.t004
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folic acid and vitamin B12 in children with CF ameliorates
red cell membrane features and reduces heat shock protein
70 membrane association
Thirty-one patients were enrolled in the single-arm trial. Three
patients withdrew from the study due to loss to follow-up and six
patients for intercurrent illness. All the other patients completed
the trial (Fig. 1). No difference in baseline measurements had been
documented between the 9 patients who dropped out the study
and the other 22 who completed the trial. No adverse events were
registered during the trial.
Supplementation with 5-MTHF and vitamin B12 significantly
increased plasma folate levels, red cell folate content and plasma
vitamin B12 levels and significantly reduced plasma homocysteine
levels in children with CF (Fig. 4). However, some of the CF
patients (n=6) did not show a total compliance to the 5-MTHF
and vitamin B12 supplementation as supported by the unmodified
values of red cell folate content, which may be considered a
marker of long-term (24 weeks) patient folate state [27,28].
At the end of the study we observed a significant increase of
PUFAs bound to PE in red cell membranes (Table 4, P=0,038) as
well as in CF monocytes (data not shown) indicating that 5-MTHF
and vitamin B12 supplementation beneficially modified the fatty
acid composition of red cell membrane phospholipids. An
increased incorporation of n-6 fatty acid accounted for the higher
proportion of PUFAs in PE after the supplementation (Table 4). In
fact, arachidonic acid (AA) bound to PE both in red cell and in
monocyte membrane was significantly increased (from
10.3161.82 to 15.9362.80, respectively, in red cells), suggesting
that a lower amount of AA may be released for generating
eicosanoids, which participate in inflammatory injury and have
been reported to be increased in CF patients [64]. In CF patients
supplemented with 5-MTHF and vitamin B12, the unsaturation
index (UI) both in red cells and in monocytes was signif-
icantly increased, indicating an improvement of membrane fluidity
(RBCs baseline UI: 144.9610.1 vs treated: 147.6469.9, P,0.05;
monocytes baseline UI: 133.5613.07 vs treated: 140.7611.63,
P=0.06). Interestingly no significant difference in plasma UI was
present in CF patients before and after supplementation (baseline
UI 122.1162.3 vs treated: 122.7262.61; P=ns).
In order to evaluate the biological effects of 5-MTHF and
vitamin B12 supplementation, we further studied a group of 11
patients, 8 compliant and 3 non-compliant, and we also
considered their clinical conditions and pharmacological treat-
ments (Table 5). 5-MTHF and vitamin B12 supplementation
induced a significant decrease in MDA red cell content in CF
patients fully compliant with supplementation (patients: 1, 3, 6, 7,
8, 9, 10, 11, Fig. 5A), suggesting an amelioration of membrane
lipid peroxidation, while in the non-compliant (patients: 2, 4, 5) we
observed either no changes or a slight increase in red cell MDA
levels. In the same CF patients, red cell membrane protein
oxidative damage was evaluated by fluorescein-5-maleimide,
which labels proteins with active thiol-groups. As shown in
Fig. 5B, 5-MTHF and vitamin B12 supplementation markedly
increased the intensity of fluorescence in compliant patients,
suggesting a reduction of the oxidative stress in red cell membrane
proteins. Patients 2, 7, 8, 10 and 11 were colonized by micro-
organisms and under antibiotic treatment at the end of the trial
(Table 5). These patients showed no or minor positive changes in
the parameters of the oxidative damaged measured.
In order to identify the proteins affected by oxidative damage in
CF RBCs the bands showing changes in fluorescence intensity
were excised and analysed by mass spectrometry. We identified
three groups of proteins, clustered according to their functions: (i)
membrane proteins, (ii) cytoskeletal proteins and (iii) chaperones,
suggesting that in CF patients the increase oxidative damage
affects the organization and the stability of plasma membrane
proteins (Table 6).
Chaperones are group proteins (i.e. heat shock proteins) that
assist and protect intracellular proteins during cell life to maintain
their functional conformation [65]. In CF patients heat shock
proteins have been reported to play a crucial role in the CFTR
protein folding but also in the impaired CFTR chloride
conductance [66]. Here, the amount of membrane associated
heat shock protein 70 (HSP70) was higher in CF patients than in
Table 5. Clinical data of subset cystic fibrosis patients.
Patient M.o. in sputum at baseline
Antibiotic treatment at
baseline
M.o. in sputum at the end of
supplementation
Antibiotic treatment at the end of
supplementation
1 no no no no
2 P. aeruginosa C azithromycin p.o. P. aeruginosa C azithromycin p.o.
tobramycin neb. tobramycin neb.
3 no no no no
4 no no no no
5 no no no no
6 no no no no
7 S. aureus no P. aeruginosa I ciprofloxacin p.o.
tobramycin neb.
8 S. aureus no P. aeruginosa I ceftazidime i.v.
tobramycin neb.
9 no no no no
10 no no H. influenzae cotrimoxazole p.o.
11 no no P. aeruginosa I ciprofloxacin p.o.
P.: Pseudomonas; S.: Staphylococcus; H.: Haemophilus; C: chronic colonization; I: intermittent colonization; NA: not applicable; p.o.: per os; neb.: nebulized; i.v.:
intravenous.
doi:10.1371/journal.pone.0004782.t005
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cells. After 5-MTHF and vitamin B12 supplementation, we
observed a marked reduction in HSP70 membrane association
in totally compliant CF patients compared to non-compliant,
indicating a reduction in red cell oxidative stress (Fig. 6).
5-MTHF and vitamin B12 supplementation also increased red
cell K
+ content with a slight but not significant increase in red cell
Na
+ content (Fig. 3). The activity of Na/K pump, Na/K/Cl
cotransport and Na/H exchange was not modified by 5-MTHF
and vitamin B12 supplementation (Fig. 3C).
Table 6. List of identified proteins displaying different degrees of oxidation in red cells from normal and cystic fibrosis patients.
Band AC Protein Description Matching peptides Coverage (%)
1 P02549 Alfa spectrin 28 43
2 P11277 Beta spectrin 26 40
3 P16157 Ankyrin 20 22
4 P02730 Band 3 10 33
5 P11171 Band 4.1 11 26
6 P11171 Band 4.1 10 24
7 P16452 Band 4.2 9 12
8 P08107 Heat Shock Protein 70 (HSP70) 16 31
The corresponding bands are indicated in Fig. 4B; AC: accession number.
doi:10.1371/journal.pone.0004782.t006
Figure 5. Effects of 5-MTHF and vitamin B12 supplementation on malondialdehyde content and membrane proteins of red blood
cells from CF patients. (A) Malondialdehyde content of red blood cells at baseline and after supplementation (B) Red cell membrane proteins
were separated by mono-dimensional electrophoresis and labelled with fluorescein-5-maleimide, which labels the proteins with active thiol-groups.
Fluorescence was detected by placing the gel on a UV light source, photographed and analyzed. CF patients are indicated by numbers from 1 to 11;
b: baseline; a: after supplementation with 5-MTHF and vitamin B12. The bands showing different fluorescence are indicated on the colloidal
Commassie stained gel with numbers from 1 to 8.
doi:10.1371/journal.pone.0004782.g005
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In the present study, we observed that CF children had red cell
folate concentrations higher than healthy controls with associated
abnormalities of red cell membranes, suggesting that the
intracellular folates might be metabolically inactive. Three
different mechanisms might be involved: (i) the inhibition of the
phosphatidylethanolamine N-methyltransferase; (ii) the downreg-
ulation of the methionine cycle or (iii) the reduced methylenete-
trahydrofolate reductase (MTHFR) activity. We exclude an
inhibition of the phosphatidylethanolamine N-methyltransferase
because the activity of this enzyme has been reported to be normal
in CF patients [67]. A down-regulation of the methionine synthase
is not plausible because, if this were the case, we would observe a
reduction of red cell folate content compared to normal controls
(Fig 2B) [59]. Thus, the remaining hypothesis is a reduced activity
of the MTHFR associated with an accumulation of folates [60] in
red cells, as we observed in erythrocytes of children with CF
(Fig. 2C). Since we did not detect differences either in the
incidence of MTHFR polymorphisms or in the amount of
MTHFR protein in CF patients compared to normal subjects,
we suggest that posttranslational modifications of the MTHFR,
such as phosphorylation [68], might favour the inactive state of
MTHFR in CF patients. In fact, supplementation with 5-MTHF,
the active form of folate, induced a further increase in red cell
folate content and a significant reduction in plasma homocysteine
levels with amelioration of plasma membrane features in CF red
cells and monocytes.
When 5-MTHF content was elevated by diet supplementation
in CF erythrocytes, we observed an increased amount of
polyunsaturated fatty acids (PUFAs), in particular of arachidonic
acid (AA, n-6 fatty acid), in CF red cell plasmamembrane
associated with increased unsaturation index. It is interesting to
note that an isolated case of a CF child treated since her birth with
active folic acid, showed increased docosahexaenoic acid (DHA, n-
3 fatty acid), which was not detectable in the present study [20].
Since AA and DHA compete for the same site of esterification on
phospholipids, the different diet of the children studied should be
taken into account. In fact, the bioavailability of PUFAs differs
between breast milk, where DHA is more abundant, and the diet
Figure 6. Effects of 5MTHF and vitamin B12 supplementation on heat shock protein 70 associated with red cell membrane from CF
patients. (A) HSP70 associated with red cell membrane from CF patients were separated by mono-dimensional electrophoresis. Normal red cells are
in line 1; red cells respectively from patient 1 (P1), patient 3 (P3) and patient 7 (P7) are in lanes 2, 4, 6 at baseline and in lanes 3, 5, 7 after treatment.
(B) Graph reporting the immuno-blot analysis for the quantification of HSP70 expression as detected by densitometry in normal controls (black bar)
and in CF patients (gray bar); data are presented as percentage of baseline values (n=11). (C) Schematic diagram of the working hypothesis. Cellular
membrane lipids and proteins are exposed to chronic oxidative stress in CF patients. The altered metabolism of polyunsaturated fatty acids (PUFAs)
contributes to cellular damage, reducing membrane fluidity and increasing pro-oxidant environment. The 5-MTHF and vitamin B12 supplementation
increases the levels of PUFAs and reduces both protein oxidative damage and HSP70 association on red cell membranes of CF patients.
doi:10.1371/journal.pone.0004782.g006
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predominance [69]. However, both these studies show increased
amount of unsaturated fatty acids in red cell membranes, which
has been reported to improve cellular membrane fluidity. The
increased levels of n-6 fatty acids, that we observed at the end of
this study, also suggests a reduced release of AA from
phospholipids to form eicosanoids that may contribute to
inflammation in CF patients [70,71].
Previous reports have shown increased susceptibility of CF red
cells to oxidative injury [36,38,39,72–74]. Here, we have chosen to
evaluate both lipid and protein oxidative damage at baseline and
after treatment. In CF red cells, we showed an increased oxidative
damage of membrane proteins at baseline, suggesting that the
lower availability of 5-MTHF and the accumulation of non-
methylated folates might amplify the cellular pro-oxidant envi-
ronment, being 5-MTHF a natural antioxidant scavenger for
peroxynitrite [42]. 5-MTHF and vitamin B12 supplementation
increased the bioavailability of active form of folic acid and
reduced free radical cell injury as supported by the reduction in
MDA red cell content and the positive changes in red cell
membrane proteins of CF children (Fig. 5). In addition, 5-MTHF
and vitamin B12 supplementation normalized CF red cell Na
+
content and increased red cell K
+ content towards values similar to
those observed in normal controls, indicating an amelioration of
membrane trafficking. The beneficial effect of 5-MTHF and
vitamin B12 supplementation on red cell membrane is also
supported by the reduction in the amount of membrane associated
heat shock protein 70 (HSP70) (Fig. 6C).
Taking into account the limitations resulting from the lack of a
control group who did not receive the vitamin supplementation,
we can only suppose that 5-MTHF and vitamin B12 treatment
might represent a new tool to ameliorate plasma membrane
features in CF children. Further studies need to be carried out in
order to evaluate the effective effects of 5-MTHF and vitamin B12
supplementation in a large population of children with CF.
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